Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Leukemia

  Free Subscription


23.07.2018

2 Am J Hematol
2 Ann Hematol
1 Biochem Biophys Res Commun
1 Biochem Pharmacol
12 Bone Marrow Transplant
2 Eur J Haematol
1 Exp Cell Res
1 J Clin Oncol
1 J Immunol
1 Leukemia
2 Proc Natl Acad Sci U S A


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Hematol

  1. NORWOOD J, Pastoret C, Luycx O, Le Coz MF, et al
    Switches of tyrosine-kinase inhibitors in chronic phase of chronic myeloid leukemia in real life.
    Am J Hematol. 2018 Jul 17. doi: 10.1002/ajh.25217.
    PubMed     Text format    

  2. FATHI AT, Hobbs G, Dey BR, Chen YB, et al
    Lenalidomide combined with mismatched microtransplantation for acute myeloid leukemia.
    Am J Hematol. 2018 Jul 17. doi: 10.1002/ajh.25218.
    PubMed     Text format    


    Ann Hematol

  3. ZHANG G, Zhang L, Yang X, Zhang X, et al
    High ETS2 expression predicts poor prognosis in acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation.
    Ann Hematol. 2018 Jul 18. pii: 10.1007/s00277-018-3440.
    PubMed     Text format    

  4. ZAPPASODI P, Marbello L, Borlenghi E, Fumagalli M, et al
    Molecular remission at the end of treatment is a necessary goal for a good outcome in ELN favorable-risk acute myeloid leukemia: a real-life analysis on 201 patients by the Rete Ematologica Lombarda network.
    Ann Hematol. 2018 Jul 15. pii: 10.1007/s00277-018-3424.
    PubMed     Text format     Abstract available


    Biochem Biophys Res Commun

  5. TAKAMI M, Katayama K, Noguchi K, Sugimoto Y, et al
    Protein kinase C alpha-mediated phosphorylation of PIM-1L promotes the survival and proliferation of acute myeloid leukemia cells.
    Biochem Biophys Res Commun. 2018 Jul 12. pii: S0006-291X(18)31544.
    PubMed     Text format     Abstract available


    Biochem Pharmacol

  6. MARIOTTO E, Bortolozzi R, Volpin I, Carta D, et al
    EB-3D a novel choline kinase inhibitor induces deregulation of the AMPK-mTOR pathway and apoptosis in leukemia T-cells.
    Biochem Pharmacol. 2018;155:213-223.
    PubMed     Text format     Abstract available


    Bone Marrow Transplant

  7. BLUM V, Heini AD, Novak U, Taleghani BM, et al
    Hematopoietic stem cell remobilization with vinorelbine and filgrastim in AML.
    Bone Marrow Transplant. 2017 Feb 13. doi: 10.1038/bmt.2017.
    PubMed     Text format    

  8. YAMASHITA T, Ikegame K, Kojima H, Tanaka H, et al
    Effective desensitization of donor-specific HLA antibodies using platelet transfusion bearing targeted HLA in a case of HLA-mismatched allogeneic stem cell transplantation.
    Bone Marrow Transplant. 2017 Feb 6. doi: 10.1038/bmt.2017.
    PubMed     Text format    

  9. CARRE M, Thiebaut-Bertrand A, Larrat S, Leroy V, et al
    Fatal autochthonous fulminant hepatitis E early after allogeneic stem cell transplantation.
    Bone Marrow Transplant. 2017 Jan 9. doi: 10.1038/bmt.2016.
    PubMed     Text format    

  10. LEGRAND F, Le Floch AC, Granata A, Furst S, et al
    Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation for high-risk AML.
    Bone Marrow Transplant. 2016 Dec 12. doi: 10.1038/bmt.2016.
    PubMed     Text format    

  11. ALBRING JC, Inselmann S, Sauer T, Schliemann C, et al
    PD-1 checkpoint blockade in patients with relapsed AML after allogeneic stem cell transplantation.
    Bone Marrow Transplant. 2016 Nov 28. doi: 10.1038/bmt.2016.
    PubMed     Text format    

  12. BILL M, Jentzsch M, Grimm J, Schubert K, et al
    Prognostic impact of the European LeukemiaNet standardized reporting system in older AML patients receiving stem cell transplantation after non-myeloablative conditioning.
    Bone Marrow Transplant. 2017 Apr 3. doi: 10.1038/bmt.2017.
    PubMed     Text format    

  13. GARNIER A, Guillaume T, Peterlin P, Bene MC, et al
    Second-degree relative donors for T-replete haploidentical allogeneic stem cell transplantation with high-dose post-transplant cyclophosphamide: toward crossing the major HLA barrier.
    Bone Marrow Transplant. 2017 Apr 3. doi: 10.1038/bmt.2017.
    PubMed     Text format    

  14. SALEM R, Massoud R, Haffar B, Mahfouz R, et al
    Dynamics of molecular response in AML patients with NPM1 and FLT3 mutations undergoing allogeneic stem cell transplant.
    Bone Marrow Transplant. 2017 Jun 5. doi: 10.1038/bmt.2017.
    PubMed     Text format    

  15. GROS FX, Cazaubiel T, Forcade E, Lechevalier N, et al
    Severe acute GvHD following administration of ipilimumab for early relapse of AML after haploidentical stem cell transplantation.
    Bone Marrow Transplant. 2017 Jun 5. doi: 10.1038/bmt.2017.
    PubMed     Text format    

  16. GEETHAKUMARI PR, Leiby B, Nair R, Alpdogan SO, et al
    Higher rates of relapse in maternal recipients of haploidentical hematopoietic stem cell transplantation from adult offspring donors for AML and myelodysplastic syndrome.
    Bone Marrow Transplant. 2017 Jul 31. doi: 10.1038/bmt.2017.
    PubMed     Text format    

  17. LAHTEENMAKI K, Wacklin P, Taskinen M, Tuovinen E, et al
    Haematopoietic stem cell transplantation induces severe dysbiosis in intestinal microbiota of paediatric ALL patients.
    Bone Marrow Transplant. 2017 Aug 7. doi: 10.1038/bmt.2017.
    PubMed     Text format    

  18. FREEMAN AT, Stover AM, Grover NS, Shea TC, et al
    Patient perspectives on physical function after allogeneic hematopoietic stem cell transplantation: a qualitative study.
    Bone Marrow Transplant. 2017 Aug 7. doi: 10.1038/bmt.2017.
    PubMed     Text format    


    Eur J Haematol

  19. BOUVIER A, Ribourtout B, Francois S, Orvain C, et al
    Donor cell-derived acute promyelocytic leukemia after allogeneic hematopoietic stem cell transplantation.
    Eur J Haematol. 2018 Jul 14. doi: 10.1111/ejh.13143.
    PubMed     Text format     Abstract available

  20. HOEKS M, van der Pol M, Middelburg R, Evers D, et al
    Bone marrow iron score as an indicator for secondary iron overload in acute myeloid leukemia patients.
    Eur J Haematol. 2018 Jul 17. doi: 10.1111/ejh.13145.
    PubMed     Text format     Abstract available


    Exp Cell Res

  21. BAMODU OA, Kuo KT, Yuan LP, Cheng WH, et al
    HDAC inhibitor suppresses proliferation and tumorigenicity of drug-resistant chronic myeloid leukemia stem cells through regulation of hsa-miR-196a targeting BCR/ABL1.
    Exp Cell Res. 2018 Jul 12. pii: S0014-4827(18)30440.
    PubMed     Text format     Abstract available


    J Clin Oncol

  22. LANCET JE, Uy GL, Cortes JE, Newell LF, et al
    CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia.
    J Clin Oncol. 2018 Jul 19:JCO2017776112. doi: 10.1200/JCO.2017.77.6112.
    PubMed     Text format     Abstract available


    J Immunol

  23. YANG TH, St John LS, Garber HR, Kerros C, et al
    Membrane-Associated Proteinase 3 on Granulocytes and Acute Myeloid Leukemia Inhibits T Cell Proliferation.
    J Immunol. 2018 Jul 18. pii: jimmunol.1800324. doi: 10.4049/jimmunol.1800324.
    PubMed     Text format     Abstract available


    Leukemia

  24. LI Z, He S, Look AT
    The MCL1-specific inhibitor S63845 acts synergistically with venetoclax/ABT-199 to induce apoptosis in T-cell acute lymphoblastic leukemia cells.
    Leukemia. 2018 Jul 15. pii: 10.1038/s41375-018-0201.
    PubMed     Text format    


    Proc Natl Acad Sci U S A

  25. ZEISIG BB, So CWE
    MLL-AF4, a double-edged sword for iPSC respecification into HSPCs.
    Proc Natl Acad Sci U S A. 2018;115:1964-1966.
    PubMed     Text format    

  26. MAZOR R, King EM, Onda M, Cuburu N, et al
    Tolerogenic nanoparticles restore the antitumor activity of recombinant immunotoxins by mitigating immunogenicity.
    Proc Natl Acad Sci U S A. 2018;115:E733-E742.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: